CDC Update to Interim Guidance for PrEP: PrEP for Injecting Drug Users
The Thailand Ministry of Health and CDC published results from a randomized controlled trial of a daily oral dose of 300 mg of tenofovir disoproxil fumarate (TDF) that showed efficacy in reducing the acquisition of HIV infection among injecting drug users. Based on these findings, CDC recommends that preexposure prophylaxis (PrEP) be considered as one of several prevention options for persons at very high risk for HIV acquisition through the injection of illicit drugs. Click here to view the updated guidance in the MMWR and click here to view the Lancet article .
|
|
|